aTyr Pharma (ATYR) Stock Overview
A clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
ATYR Community Fair Values
Create NarrativeSee what 64 others think this stock is worth. Follow their fair value or set your own to get alerts.
aTyr Pharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.00 |
| 52 Week High | US$7.29 |
| 52 Week Low | US$0.68 |
| Beta | 0.79 |
| 1 Month Change | -7.41% |
| 3 Month Change | -83.31% |
| 1 Year Change | -62.26% |
| 3 Year Change | -60.63% |
| 5 Year Change | -69.70% |
| Change since IPO | -99.63% |
Recent News & Updates
Recent updates
Will aTyr Pharma (NASDAQ:ATYR) Spend Its Cash Wisely?
Mar 27
aTyr Pharma: Two 2025 Data Readouts Could Provide Inflection Point
Sep 09We Think aTyr Pharma (NASDAQ:ATYR) Needs To Drive Business Growth Carefully
Jul 13We're Hopeful That aTyr Pharma (NASDAQ:LIFE) Will Use Its Cash Wisely
Feb 03Here's Why We're Not Too Worried About aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation
Oct 04Here's Why We're Watching aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation
May 06We're Keeping An Eye On aTyr Pharma's (NASDAQ:LIFE) Cash Burn Rate
Jan 04aTyr Pharma rises on U.S. patent for anti-neuropilin-2 monoclonal antibodies
Sep 29aTyr Pharma stock rises on FDA fast track status for efzofitimod for lung disease
Sep 13aTyr Pharma gains with FDA Fast Track status for lead asset
Aug 11We Think aTyr Pharma (NASDAQ:LIFE) Needs To Drive Business Growth Carefully
May 10Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?
Jan 24aTyr Pharma: Successful Proof Of Concept In Pulmonary Sarcoidosis
Dec 28aTyr Stock Is Buoyant On Highly-Promising Lung Disease Data - Wait For Hype To Die Down And Buy
Sep 24Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?
Sep 23Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?
May 22aTyr Pharma, Inc. (NASDAQ:LIFE) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
Mar 25Did You Miss aTyr Pharma's (NASDAQ:LIFE) Impressive 103% Share Price Gain?
Feb 09
Shareholder Returns
| ATYR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 4.9% | 0.4% | -1.5% |
| 1Y | -62.3% | -0.7% | 14.4% |
Return vs Industry: ATYR underperformed the US Biotechs industry which returned -0.7% over the past year.
Return vs Market: ATYR underperformed the US Market which returned 14.4% over the past year.
Price Volatility
| ATYR volatility | |
|---|---|
| ATYR Average Weekly Movement | 28.0% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ATYR's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ATYR's weekly volatility has increased from 17% to 28% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 61 | Sanjay Shukla | atyrpharma.com |
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; and in Phase 1b/2a clinical trial to treat other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders.
aTyr Pharma, Inc. Fundamentals Summary
| ATYR fundamental statistics | |
|---|---|
| Market cap | US$99.95m |
| Earnings (TTM) | -US$66.64m |
| Revenue (TTM) | n/a |
Is ATYR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ATYR income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$54.23m |
| Gross Profit | -US$54.23m |
| Other Expenses | US$12.40m |
| Earnings | -US$66.64m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.68 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ATYR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/16 11:31 |
| End of Day Share Price | 2025/10/16 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
aTyr Pharma, Inc. is covered by 20 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Birchenough | BMO Capital Markets Equity Research |
| Prakhar Agrawal | Cantor Fitzgerald & Co. |
| Ilya Zubkov | Freedom Broker |